The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer.


The effects of enzalutamide monotherapy on prostate tumor downsizing and multiparametric MRI are currently unknown. Here we present the first case in literature of a patient with high-grade prostate cancer who underwent 3 months of neoadjuvant enzalutamide, for which the effects on mpMRI and histology were determined. Tumor size reduction and downstaging were noted. Neoadjuvant enzalutamide resulted in an increase in ADC value on the DWI-MRI sequences. Histological changes were also observed.

More about this publication

Urology case reports
  • Volume 7
  • Pages 67-9
  • Publication date 01-07-2016

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.